Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215949 · ClinicalTrials.gov registry record · Phase 3
Zilucoplan for Severe gMG Exacerbations
A Phase 3 study of Generalized Myasthenia Gravis (gMG), sponsored by Miriam Freimer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07215949 is a Phase 3 study of Generalized Myasthenia Gravis (gMG) that is actively recruiting participants, run by Miriam Freimer. The registered enrollment target is 15 participants, below the 57-participant average among 4 other Generalized Myasthenia Gravis (gMG) trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07215949, a Phase 3 study of Generalized Myasthenia Gravis (gMG), is actively recruiting participants, sponsored by Miriam Freimer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
Conditions Studied
Interventions
- DRUG Zilucoplan®
Study Locations (1)
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215949
The ClinicalTrials.gov registry entry for NCT07215949 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 57-participant average among 4 other Generalized Myasthenia Gravis (gMG) trials with a reported enrollment target (74% lower). The listed sponsor is Miriam Freimer, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis (gMG) appearing as the primary indexed condition, and to 1 intervention - of which Zilucoplan® is the first listed.
NCT07215949 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07215949 about?
NCT07215949 is a clinical study titled "Zilucoplan for Severe gMG Exacerbations". This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
What is the current status of trial NCT07215949?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2026-01-20. Estimated completion is 2028-04-01.
What conditions does trial NCT07215949 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis (gMG).
What interventions are being tested in trial NCT07215949?
The interventions under investigation include: Zilucoplan® (DRUG).
Who is sponsoring clinical trial NCT07215949?
This trial is sponsored by Miriam Freimer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215949 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis (gMG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
RECRUITING
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RECRUITING
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.